Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CME GroupBSP:CHME34 -0.93%86 Cyclically Adjusted PB Ratio is 2.93 as of Aug. 07, 2026, which is 19% above its 10-year median of 2.46. GuruFocus rates BSP:CHME34 with a GF Score™ of 86/100 and a GF Value™ of R$68.92 (Fairly Valued). The stock has 3 warning signs investors should review. Among 609 Capital Markets companies, CME Group ranks worse than 74.88% on this metric.
The historical rank and industry rank for CME Group's Cyclically Adjusted PB Ratio or its related term are showing as below:
BSP:CHME34'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.49 Med: 2.46 Max: 3.74
Current: 3.03
During the past years, CME Group's highest Cyclically Adjusted PB Ratio was 3.74. The lowest was 1.49. And the median was 2.46.
BSP:CHME34's Cyclically Adjusted PB Ratio is ranked worse than 74.88% of 609
companies
in the Capital Markets industry
Industry Median: 1.29
vs BSP:CHME34: 3.03
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
CME Group's adjusted book value per share data for the three months ended in Jun. 2026 was R$18.912. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$22.90 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
CME Group (BSP:CHME34) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
CME Group Cyclically Adjusted PB Ratio Related Terms
CME Group Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for CME Group's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:CHME34 vs ICE, MCO, SPGI: Cyclically Adjusted PB Ratio Comparison
For the Financial Data & Stock Exchanges subindustry, CME Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group Cyclically Adjusted PB Ratio vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where CME Group's Cyclically Adjusted PB Ratio falls into.
CME Group Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
CME Group's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 2.93 mean?
CME Group (BSP:CHME34) has a Cyclically Adjusted PB Ratio of 2.93 as of Aug. 07, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on CME Group and its competitors. This is 19% above median its historical median of 2.46. Over the past decade, CME Group's Cyclically Adjusted PB Ratio has ranged from 1.49 to 3.74. According to the industry distribution chart, CME Group ranks #456 out of 609 companies in the Capital Markets industry, placing it in the top 74.9%.
Is CME Group's Cyclically Adjusted PB Ratio too high?
CME Group's current Cyclically Adjusted PB Ratio of 2.93 is 19% above median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 1.49 to a high of 3.74. The Capital Markets industry median Cyclically Adjusted PB Ratio is 1.29. CME Group's value of 2.93 is 127.1% above this industry median. Based on the distribution chart, CME Group ranks #456 out of 609 companies in the Capital Markets industry, which is below the industry midpoint. Overall, CME Group has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CME Group's Cyclically Adjusted PB Ratio compare to ICE and MCO?
According to the Capital Markets industry distribution chart, CME Group ranks #456 out of 609 companies for Cyclically Adjusted PB Ratio. This places CME Group in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.29. CME Group's value of 2.93 is 127.1% above this benchmark. Historically, CME Group's own Cyclically Adjusted PB Ratio has ranged from 1.49 to 3.74 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 1.29, CME Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Capital Markets company?
The median Cyclically Adjusted PB Ratio among Capital Markets companies is 1.29, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CME Group's current Cyclically Adjusted PB Ratio of 2.93 is 127.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on CME Group and its competitors. For the Capital Markets industry, the median Cyclically Adjusted PB Ratio is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current Cyclically Adjusted PB Ratio is 2.93, which is 19% above median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (BSP:CHME34) is currently considered Fairly Valued. The stock's GF Value™ is R$68.92, compared to a current price of R$67.13 — trading 2.6% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 2.93, which is 19% above median its 10-year median of 2.46 and 127.1% above the Capital Markets industry median of 1.29. CME Group's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For CME Group (BSP:CHME34), the current Cyclically Adjusted PB Ratio is 2.93 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (BSP:CHME34) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be undervalued.
The current stock price of R$67.13 is trading 2.6% below its estimated GF Value™ of R$68.92.
GuruFocus considers CME Group to be Fairly Valued.
Key valuation signals for BSP:CHME34:
Cyclically Adjusted PB Ratio: 2.93 (19% above median its 10-year median of 2.46)
GF Value™: R$68.92 vs. price of R$67.13 (2.6% below fair value)
Industry Position: 127.1% above the Capital Markets median (#456 of 609)
No single metric tells the full story. See the BSP:CHME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
86GF Score
Get the complete analysis for BSP:CHME34
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:CHME34 has been successfully added to your 
